We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current VYNE market cap is 32.31M. The company's latest EPS is USD -1.9288 and P/E is -1.14.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 114k | 76k | 98k | 198k | 121k |
| Operating Income | -6.23M | -6.83M | -7.38M | -10.4M | -13.09M |
| Net Income | -6.58M | -6.19M | -6.25M | -9.41M | -12.16M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 20.99M | 14.76M | 477k | 424k |
| Operating Income | -76.24M | -198.2M | -68.03M | -34.3M | -29.26M |
| Net Income | -73.7M | -255.83M | -73.33M | -23.21M | -28.45M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 19.27M | 97.69M | 91.68M | 86.65M | 76.2M |
| Total Liabilities | 7.76M | 8.95M | 8.31M | 11.78M | 12.66M |
| Total Equity | 11.51M | 88.74M | 83.37M | 74.87M | 63.54M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 79.17M | 93.74M | 67.05M | 40.76M | 97.69M |
| Total Liabilities | 10.66M | 56.25M | 18.41M | 9.35M | 8.95M |
| Total Equity | 68.51M | 37.49M | 48.64M | 31.2M | 88.74M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -20.2M | -25.34M | -7.98M | -16.46M | -24.97M |
| Investing | 5M | -57.35M | -3.57M | 15.45M | 10.63M |
| Financing | -269k | 82.39M | -4k | -7k | -9k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -65.1M | -137.08M | -56.37M | -29.2M | -25.34M |
| Investing | 41.37M | 89.11M | 1.03M | 15.67M | -57.35M |
| Financing | 4.99M | 61.81M | 39.78M | 1.65M | 82.39M |
| Market Cap | 32.31M |
| Price to Earnings Ratio | -1.14 |
| Price to Sales Ratio | 76.66 |
| Price to Cash Ratio | 1.06 |
| Price to Book Ratio | 0.37 |
| Dividend Yield | - |
| Shares Outstanding | 14.75M |
| Average Volume (1 week) | 46.38k |
| Average Volume (1 Month) | 62.35k |
| 52 Week Change | -7.20% |
| 52 Week High | 4.29 |
| 52 Week Low | 1.57 |
| Spread (Intraday) | 49.8 (99.6%) |
| Company Name | VYNE Therapeutics Inc |
| Address |
1521 concord pike suite 201 wilmington, delaware 19810 |
| Website | https://vynetherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
